CAR T-cell therapies targeting specific antigens show potential for treating pediatric CNS tumors
New CAR T-cell therapies show promise for pediatric brain tumors
This narrative review synthesizes 18 studies, including preclinical and early-phase clinical trials, regarding CAR T-cell therapy for pediat…
CAR T-cell therapy is showing potential to shrink tumors and extend life in children with aggressive brain cancers like DIPG.
Targeted cytokine delivery platforms in canine oncology provide data for human immuno-oncology dose selection
Cytokine Therapies Show Potential for Treating Canine Cancers
This mini review synthesizes evidence on targeted cytokine delivery platforms, such as IL-12 and IFN-beta, in dogs with various spontaneous …
New research explores how targeted cytokine delivery systems can treat various cancers in dogs and provide data for future human cancer trea…
Intracranial immunotherapy delivery does not improve survival for pediatric high-grade glioma compared to systemic administration
Intracranial Delivery Shows Higher Neurotoxicity Risk in Pediatric Brain Tumors
This meta-analysis of 22 studies evaluated intracranial versus systemic immunotherapy delivery in pediatric patients with high-grade and dif…
New analysis shows that while delivery methods do not change survival for pediatric brain tumors, some routes carry a higher risk of severe …
Recurrence patterns in high-grade glioma after standard chemoradiotherapy: a retrospective review
Why tumors grow back inside the radiation beam, not just at the edges
This retrospective single-center review of 41 patients with high-grade glioma found that central recurrence was the most common pattern (36.…
New data shows brain tumors often return in the middle of the radiation zone, suggesting biology, not just targeting errors, drives failure.
GSC-associated gene signature predicts survival in adult and pediatric high-grade glioma patients
New Brain Tumor Test Predicts Survival More Accurately
This cohort study evaluated a GSC-associated gene signature involving the FAM86B1/FAM86B2 axis in adult and pediatric high-grade glioma pati…
A new model uses specific genes to predict how long patients might live with aggressive brain tumors.
Review of STING agonists for high-grade and diffuse midline glioma discusses systemic toxicity and delivery constraints
New Brain Drug Target Could Wake Up the Immune System
This narrative review examines the potential of STING agonists, cyclic dinucleotides, and related compounds for treating high-grade glioma a…
A new brain drug target aims to wake up the immune system's defenses against dangerous, hard-to-treat tumors that hide from the body's natur…
Locoregional CAR T-cell delivery reduces severe adverse events in high-grade glioma patients
Could a new way to deliver brain cancer therapy make it safer and more effective?
A meta-analysis of 14 clinical trials involving 194 high-grade glioma patients found locoregional CAR T-cell delivery was associated with re…
Delivering brain cancer therapy directly to the tumor instead of through the bloodstream cuts severe side effects by more than 60% and shows…
Research across Cancer
Related studies from across the Cancer family.
Peer support may impact fear of disease progression and psychological symptoms in patients with glioma
Peer support may ease fear in glioma patients
This is a protocol for a systematic review and meta-analysis regarding the impact of peer support on fear of disease progression, fatigue, d…
A new meta-analysis protocol will examine whether peer support reduces fear of disease progression in glioma patients.
Symptomatic radiation necrosis occurs in 5.7% of intracranial brachytherapy patients
Brachytherapy for brain tumors: 5.7% risk of radiation necrosis
This meta-analysis of 3666 patients undergoing intracranial brachytherapy for glioma, brain metastases, or meningioma found a pooled inciden…
About 1 in 18 patients who get internal radiation for brain tumors develop symptomatic radiation necrosis, a new analysis finds.
Immunohistochemical profiling helps differentiate synchronous primary breast invasive carcinoma from metastatic ovarian carcinoma
One woman diagnosed with two different types of cancer simultaneously
This case report and literature review describes a patient with concurrent primary breast cancer and metastatic high-grade serous ovarian ca…
A rare case reveals how one patient can have both breast and ovarian cancer at once, highlighting a complex diagnostic challenge.
MRI Radiomics Predicts TERTp Mutation in Glioma with Moderate Accuracy
MRI Radiomics Help Predict TERTp Mutation in Glioma Patients
Meta-analysis of 14 studies shows MRI radiomics predicts TERTp mutation in glioma with AUC 0.79; combined models improve accuracy to 0.82.
New analysis shows MRI-based radiomics can help predict specific genetic mutations in glioma, potentially aiding early diagnosis and treatme…
NODI parameters ODI and V-ISO differentiate gliomas from brain metastases in contrast-enhancing regions
Brain scan technique helps tell gliomas from metastases
This meta-analysis evaluates the use of Neurite orientation dispersion and density imaging (NODDI) to distinguish gliomas from brain metasta…
A new imaging method may help doctors distinguish between gliomas and brain metastases without invasive biopsy.
Follicular T cell subsets and tertiary lymphoid structures may guide immunotherapy in ovarian cancer
New immune targets offer hope for ovarian cancer patients
This narrative review synthesizes evidence on follicular T cell subsets, tertiary lymphoid structures, and other immune features in ovarian …
A review highlights new immune system features that could help doctors predict treatment success and find better ways to fight ovarian cance…
Intensity-modulated radiotherapy reduces acute and delayed G2+GI toxicities versus 3D-CRT in high-risk prostate cancer
Post hoc analysis shows IMRT reduces radiation side effects for high-risk prostate cancer
This post hoc analysis of a Phase III randomized controlled trial evaluated intensity-modulated radiotherapy (IMRT) versus three-dimensional…
A post hoc analysis of a Phase III trial found that intensity-modulated radiotherapy reduced radiation side effects compared to older techni…
Deep learning models for glioma segmentation achieve high whole tumor accuracy with DSC 0.860
New AI tools show high accuracy for mapping brain tumors before surgery
This systematic review and meta-analysis of 36 deep learning models for preoperative glioma segmentation found high whole tumor segmentation…
AI models mapped brain tumors with high accuracy, but performance varied. Training on specific datasets helped, yet no single factor fully e…
Case report details multimodal treatment for aggressive thyroid carcinoma
First new treatment combination in six months stabilizes advanced thyroid cancer
A 61-year-old man with papillary thyroid carcinoma achieved disease stabilization after thyroidectomy, radiotherapy, and targeted therapy. T…
A 61-year-old man with advanced thyroid cancer saw his disease stop growing after a specific mix of treatments within six months of his diag…
Systematic review of preclinical CBD effects in canine cancers
Lab tests suggest CBD may help treat cancer in dogs
This is a systematic review of preclinical studies on cannabidiol for canine cancers. It synthesizes evidence of antiproliferative and proap…
Lab tests suggest CBD may help treat cancer in dogs by slowing growth and triggering cell death, though human use remains unproven.
Case report of YL205 antibody-drug conjugate in platinum-resistant ovarian carcinoma
First patient achieves complete response with new ovarian cancer drug YL205
This is a single-patient case report of a 40-year-old woman with platinum-resistant, BRCA-wildtype high-grade serous ovarian carcinoma treat…
A single patient with advanced ovarian cancer achieved a complete response after 24 weeks of treatment with YL205, a new antibody-drug conju…
Systematic review explores metabolic-immune axis in glioma progression and resistance
Metabolic-immune link in glioma opens new treatment avenues
This systematic review synthesizes evidence on the metabolic-immune interplay in glioma. It finds that metabolic reprogramming and immune mi…
A systematic review reveals how metabolic reprogramming and immune evasion work together in glioma, pointing to new targets for therapy.
Questions about High-grade glioma
Does delivering CAR T-cells locally reduce severe side effects in high-grade glioma?
Delivering CAR T-cells directly into the tumor or brain ventricles significantly lowers severe side effects compared to giving them through the bloodstream for high-grade glioma patients.
Full answer →Can a specific gene signature predict survival for high-grade glioma patients?
Yes, specific gene signatures can predict survival for high-grade glioma patients by analyzing tumor biology, immune interactions, and cellular processes like autophagy.
Full answer →What is the most common way high-grade glioma comes back after standard treatment?
After standard surgery and radiation, high-grade glioma most often returns in the center of the original tumor area or just at the edge of the radiation field.
Full answer →